Back

Potential benefits of prasugrel and ticagrelor is diabetics are not substantiated by the Food and Drug Administration adverse event repository

European Heart Journal - Cardiovascular Pharmacotherapy

14 February 2018
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Impact of potent P2Y12 inhibitors in adverse events reduction in diabetic patients with Acute Coronary Syndromes. An analysis from ACHILLES Registry.
2 September 2019
thumbnail
Congress Presentation
Analyzing the economic ramifications of the broad implementation of generic prasugrel
31 August 2024
thumbnail
Congress Presentation
Prasugrel versus ticagrelor in ST-elevation myocardial infarction, a real-world cohort
25 March 2023
thumbnail
Congress Presentation
Feasibility and outcomes of tailored antiplatelet therapy at a safety-net hospital
21 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources